Reig Jofre is preparing for possible new acquisitions, and continues with the formula that worked with the Swedish Bioglan in 2009 or the integration of Natraceutical in 2015. The pharmaceutical shareholders' meeting, of which the founding family holds 63% of the capital, has approved the option to issue new ordinary shares and the possibility of issuing series B for the first time, without voting rights, as well as debt, from bonds to convertible bonds or warrants. All of this is to have "new financing tools" to face possible acquisitions "if they have a strategic fit", according to the company's CEO, Ignasi Biosca, representative of the third family generation. Among the possible options for inorganic growth would be in the international commercial sphere markets where they are not yet present, such as Italy or Germany, or acquisitions to complement their activity where they already operate, such as France, Poland, or the United Kingdom, he added at a meeting with journalists.

Reig Jofre, a Catalan family-owned pharmaceutical company, earned €10.5 million last year, 11% more than the previous year, and posted revenues of €337 million, up 7%, driven by a strong external push, as almost €60 out of every €100 were generated abroad. This week, it inaugurated an expansion that doubles the production capacity of its Swedish subsidiary, Bioglan. And in 2025, it celebrated its first decade on the stock market, since its merger with the former Natraceutical. The listing, which has led to around 6,000 shareholders today, has been a positive experience, according to its CEO, Ignasi Biosca, representing the third generation of owners of the company, who receivesCompanies at its Sant Joan Despí plant, where they produce high-precision anesthetics for the Japanese market. The fact is that the stock market, he adds, has been a way to reinforce the group's commitment to innovation, especially technological innovation, and also to boost its shift from traditional chemical-based medicines to biotechnology-based medicines, which offer greater flexibility, compared to prescription drugs, which, after years of public pressure to lower their prices, are reported to be selling more than they are producing.